Compare Abbott Laboratories (ABT) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Entegris Inc — how do they compare? Abbott Laboratories trades at $110.9 (market cap $187.95B), while Entegris Inc trades at $161.14 (market cap $22.95B). The key difference: Abbott Laboratories is far larger — about 8.2× Entegris Inc's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | ENTG | |
|---|---|---|
Market Cap | $187.95B | $22.95B |
Sector | Health | Technology |
52-Week High | $136.62 | $184.00 |
52-Week Low | $82.57 | $68.80 |
Enterprise Value | $214.96B | $26.16B |
Dividend Yield | 2.32% | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
ENTG trades at $159.66, up 10.71% in 24 hours, reflecting strong momentum driven by Q2 2026 earnings beats and AI-driven semiconductor demand. The stock is near its 52-week high with bullish technical indicators and a consensus price target of $188.67. Revenue growth and margin expansion highlight operational strength, though elevated P/E and P/S ratios signal high valuation expectations.
Outlook is positive with continued earnings growth potential from semiconductor industry tailwinds, but risks include valuation sensitivity and competitive pressures. The stock offers upside to analyst targets but requires monitoring of execution and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
